{
    "root": "30dccf40-ebb5-8bfd-e063-6394a90adeab",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clobazam",
    "value": "20250321",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "CLOBAZAM",
            "code": "2MRO291B4U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31413"
        }
    ],
    "indications": {
        "text": "clobazam tablets indicated adjunctive treatment seizures associated lennox-gastaut syndrome ( lgs ) patients 2 years age older .",
        "doid_entities": [
            {
                "text": "lennox-gastaut syndrome (DOID:0050561)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050561"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "lennox-gastaut syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_2382"
            }
        ]
    },
    "contraindications": {
        "text": "doses 5 mg/day administer two divided doses ( 2.1 ) patients \u226430 kg body weight : initiate 5 mg daily titrate tolerated 20 mg daily ( 2.1 ) patients > 30 kg body weight : initiate 10 mg daily titrate tolerated 40 mg daily ( 2.1 ) adjustment needed following groups : geriatric patients ( 2.4 , 8.5 ) known cyp2c19 poor metabolizers ( 2.5 ) mild moderate hepatic impairment ; information severe hepatic impairment ( 2.7 , 8.8 ) administer whole , broken half along score , crush mix applesauce ( 2.3 ) tablets taken without food ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "clobazam tablets 10 mg white off-white , oval tablets functional scoring one side engraved `` u 1 `` side supplied follows : bottles 100 ndc 51407-585-01 clobazam tablets 20 mg white off-white , oval tablets functional scoring one side engraved `` u 2 `` side supplied follows : bottles 100 ndc 51407-586-01",
    "adverseReactions": "clobazam contraindicated patients history hypersensitivity ingredients . hypersensitivity included serious dermatological [ ( 5.6 , 5.7 ) ] .",
    "indications_original": "Clobazam tablets are indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.",
    "contraindications_original": "For doses above 5 mg/day administer in two divided doses ( 2.1 ) Patients \u226430 kg body weight: Initiate at 5 mg daily and titrate as tolerated up to 20 mg daily ( 2.1 ) Patients >30 kg body weight: Initiate at 10 mg daily and titrate as tolerated up to 40 mg daily ( 2.1 ) Dosage adjustment needed in following groups: Geriatric patients ( 2.4 , 8.5 ) Known CYP2C19 poor metabolizers ( 2.5 ) Mild or moderate hepatic impairment; no information for severe hepatic impairment ( 2.7 , 8.8 ) Administer whole, broken in half along the score, or crush and mix in applesauce ( 2.3 ) Tablets can be taken with or without food ( 2.3 )",
    "warningsAndPrecautions_original": "Clobazam tablets 10 mg are white to off-white, oval tablets with functional scoring on one side and engraved with \"U 1\" on the other side and are supplied as follows:\n                  \n                  Bottles of 100       NDC 51407-585-01\n                  \n                  Clobazam tablets 20 mg are white to off-white, oval tablets with functional scoring on one side and engraved with \"U 2\" on the other side and are supplied as follows:\n                  \n                  Bottles of 100       NDC 51407-586-01",
    "adverseReactions_original": "Clobazam is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients. Hypersensitivity reactions have included serious dermatological reactions [see\n \n  \n                        Warnings and Precautions (5.6, 5.7)\n                     ].",
    "drug": [
        {
            "name": "Clobazam",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31413"
        }
    ]
}